|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
|
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Investments—non-controlled/non-affiliated, at fair value (amortized cost of $382,268 and $311,762, respectively) | |||||||
| Cash, cash equivalents and restricted cash | |||||||
| Derivative assets, at fair value (Note 5) | |||||||
| Deferred offering costs | |||||||
| Receivable for investments sold | |||||||
| Due from Investment Adviser | |||||||
| Interest and other income receivable from investments | |||||||
| Receivable for issuance of common shares of beneficial interest | |||||||
| Prepaid expenses and other assets | |||||||
| Total assets | |||||||
| LIABILITIES | |||||||
| Secured borrowings (Note 6) | |||||||
| Payable for investments purchased | |||||||
| Derivative liabilities, at fair value (Note 5) | |||||||
| Interest and credit facility fees payable (Note 6) | |||||||
| Dividend payable (Note 8) | |||||||
| Incentive fees payable (Note 4) | |||||||
| Administrative service fees payable (Note 4) | |||||||
| Deferred financing costs payable | |||||||
| Deferred offering costs payable | |||||||
| Accrued organizational expenses | |||||||
| Deferred income | |||||||
| Other accrued expenses and liabilities | |||||||
| Total liabilities | |||||||
| NET ASSETS | |||||||
| Common shares of beneficial interest, $0.001 par value; unlimited shares authorized; 11,709,773 and 9,666,829 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | |||||||
| Paid-in capital in excess of par value | |||||||
| Total distributable earnings (loss) | |||||||
| Total net assets | |||||||
| NET ASSETS PER SHARE (in dollars per share) |
Loading...